Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERCC1 | P07992 | 1/20 | 0.51 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.51 |
| ▸ | ESR1 | P03372 | 2/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | ELANE | P08246 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | CARM1 | Q86X55 | 3/20 | 0.44 |
| ▸ | PRMT6 | Q96LA8 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | FAAH | O00519 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24668087 | 0.86 | ERCC1 (0.55) | ERCC1ERCC4KMT2ASMN1; SMN2NPC1 | |
| SCHEMBL26418205 | 0.84 | ERCC1 (0.54) | ERCC1ERCC4KMT2ASMN1; SMN2NPC1 | |
| SCHEMBL24668340 | 0.83 | ERCC1 (0.53) | ERCC1ERCC4KMT2ASMN1; SMN2NPC1 | |
| SCHEMBL26698316 | 0.83 | KMT2A (0.53) | ESR1HIF1AKMT2ASMN1; SMN2RECQL | |
| SCHEMBL12131750 | 0.82 | ERCC1 (0.70) | ERCC1ERCC4KMT2AMEN1GAA | |
| SCHEMBL22060059 | 0.81 | KMT2A (0.62) | ERCC1ERCC4KMT2ASMN1; SMN2NPC1 | |
| SCHEMBL12757447 | 0.81 | ALDH1A1 (0.62) | ERCC1ERCC4KMT2ASMN1; SMN2NPC1 | |
| SCHEMBL22060073 | 0.80 | NPC1 (0.62) | ERCC1ERCC4KMT2ASMN1; SMN2NPC1 | |
| SCHEMBL24558042 | 0.77 | ERCC1 (0.64) | ERCC1ERCC4KMT2AMEN1ALDH1A1 | |
| SCHEMBL8139001 | 0.77 | L3MBTL1 (0.49) | ESR1HIF1AKMT2ASMN1; SMN2RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238436-A1 | COMPOSITIONS INCLUDING CONJUGATED THERAPY ENHANCERS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-07-18 | — | — | US | disclosed |
| US-20230128688-A1 | DIRECTED CONJUGATION TECHNOLOGIES | KLEO PHARMACEUTICALS, INC. | 2023-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230128688-A1 | DIRECTED CONJUGATION TECHNOLOGIES | CD2BP2, CD2, CD47 | ERCC1 3649/4885ERCC4 3737/4885ESR1 991/4885 |
| US-20240238436-A1 | COMPOSITIONS INCLUDING CONJUGATED THERAPY ENHANCERS | LGMN, LPXN, LY96 | ERCC1 4251/4885ERCC4 4396/4885ESR1 409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.